Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
Safety Signal in Phase 2 Deals a Setback to BioAge Labs’ Muscle-Preserving Obesity Drug
MedCity News December 8, 2024
BioAge Labs said the potential safety problem was observed in some who received experimental drug azelaprag, which is being tested as a monotherapy and in combination with Eli Lilly obesity medication Zepbound. No safety signals were observed in those who received Zepbound alone.
The combination of an experimental BioAge Labs drug with the approved Eli Lilly obesity medication Zepbound has hit a major setback: a safety signal observed in some clinical trial participants that has led the biotech to stop the closely watched mid-stage study.
The worrisome signal is elevated liver enzymes, BioAge disclosed after Friday’s market close. For BioAge’s drug, azelaprag, or for any medication, higher levels of such enzymes are a potential sign of drug toxicity. The company...
Today's Sponsors
Today's Sponsor